» Articles » PMID: 25503498

Diagnosis and Management of Mitochondrial Disease: a Consensus Statement from the Mitochondrial Medicine Society

Abstract

Purpose: The purpose of this statement is to review the literature regarding mitochondrial disease and to provide recommendations for optimal diagnosis and treatment. This statement is intended for physicians who are engaged in diagnosing and treating these patients.

Methods: The Writing Group members were appointed by the Mitochondrial Medicine Society. The panel included members with expertise in several different areas. The panel members utilized a comprehensive review of the literature, surveys, and the Delphi method to reach consensus. We anticipate that this statement will need to be updated as the field continues to evolve.

Results: Consensus-based recommendations are provided for the diagnosis and treatment of mitochondrial disease.

Conclusion: The Delphi process enabled the formation of consensus-based recommendations. We hope that these recommendations will help standardize the evaluation, diagnosis, and care of patients with suspected or demonstrated mitochondrial disease.

Citing Articles

Clinical manifestations and pathogenesis of mitochondrial dysfunction in short stature.

Jiang Y, Wan Z, Zhang X, Du H, Yang Y, Pan H World J Pediatr. 2025; .

PMID: 40009295 DOI: 10.1007/s12519-025-00881-y.


Therapeutic Approach to Epilepsy in Patients with Mitochondrial Diseases.

Na J, Lee Y Yonsei Med J. 2025; 66(3):131-140.

PMID: 39999988 PMC: 11865870. DOI: 10.3349/ymj.2024.0325.


NADH Reductive Stress and Its Correlation with Disease Severity in Leigh Syndrome: A Pilot Study Using Patient Fibroblasts and a Mouse Model.

Ishima T, Kimura N, Kobayashi M, Watanabe C, Jimbo E, Kobayashi R Biomolecules. 2025; 15(1).

PMID: 39858433 PMC: 11764390. DOI: 10.3390/biom15010038.


Mitochondrial diseases: from molecular mechanisms to therapeutic advances.

Wen H, Deng H, Li B, Chen J, Zhu J, Zhang X Signal Transduct Target Ther. 2025; 10(1):9.

PMID: 39788934 PMC: 11724432. DOI: 10.1038/s41392-024-02044-3.


Long-term prognostic factors and outcomes in mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes: a clinical and biochemical marker analysis.

Gao R, Gu L, Zuo W, Wang P Front Neurol. 2024; 15:1491283.

PMID: 39697439 PMC: 11652343. DOI: 10.3389/fneur.2024.1491283.


References
1.
Chinnery P, Turnbull D . Epidemiology and treatment of mitochondrial disorders. Am J Med Genet. 2001; 106(1):94-101. DOI: 10.1002/ajmg.1426. View

2.
Haas R, Parikh S, Falk M, Saneto R, Wolf N, Darin N . The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab. 2008; 94(1):16-37. PMC: 2810849. DOI: 10.1016/j.ymgme.2007.11.018. View

3.
Harris R, Munroe J, Farmer B, Kim K, Jenkins P . Action of halothane upon mitochondrial respiration. Arch Biochem Biophys. 1971; 142(2):435-44. DOI: 10.1016/0003-9861(71)90507-8. View

4.
Westover J, Goodman S, Frerman F . Binding, hydration, and decarboxylation of the reaction intermediate glutaconyl-coenzyme A by human glutaryl-CoA dehydrogenase. Biochemistry. 2001; 40(46):14106-14. DOI: 10.1021/bi015637p. View

5.
Hargreaves I, Sheena Y, Land J, Heales S . Glutathione deficiency in patients with mitochondrial disease: implications for pathogenesis and treatment. J Inherit Metab Dis. 2005; 28(1):81-8. DOI: 10.1007/s10545-005-4160-1. View